Cystic fibrosis testing can be challenging for laboratories. Even though screening is recommended for all ethnicities, it can be difficult to provide reliable results for everyone, since most CFTR assays were designed based on outdated, ethnically-homogeneous data. Additionally, some assay workflows can be time-consuming, cost-prohibitive, or cumbersome for labs to use.
In this event, Asuragen is pleased to unveil the AmplideX® PCR/CE CFTR Kit*, which is designed to provide the broadest coverage** of the U.S. population of any available targeted kit, with an easy-to-implement workflow. Recent large-scale diverse datasets informed assay design to bridge coverage gaps left by other targeted assays, while the application of AmplideX technology streamlines the testing process.
This event will include a 4 hour LIVE schedule starting at 11am EST/8am PST on January 20, 2022 along with one year of continually updated content from Jan 2022 – Jan 2023.
Register now for access to:
For more information on the AmplideX PCR/CE CFTR Kit*, visit Asuragen.com/CFTR.
*For Research Use Only. Not for use in diagnostic procedures.
**Based on Beauchamp KA, et al. Genet Med. 2019.